Clinical trials in Tyler, TX

70 recruiting studies have a site in or near Tyler, TX, Texas.

Top conditions here

All conditions

Showing 40 of 70 studies

RecruitingPhase 3NCT07213674

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Sponsor: Amgen

Arlington, TX · Dallas, TX · Houston, TX · +43 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Dallas, TX · Houston, TX · +51 more sites

RecruitingPhase 3NCT06819878

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Hoffmann-La Roche

Arlington, TX · El Paso, TX · Georgetown, TX · +92 more sites

RecruitingPhase 3NCT07185009

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Sponsor: Sanofi

Kingwood, TX · Lubbock, TX · San Antonio, TX · +34 more sites

RecruitingPhase 3NCT07365995

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Sponsor: BioNTech SE

Austin, TX · Houston, TX · Tyler, TX · +18 more sites

RecruitingPhase 2NCT07697456

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Sponsor: AbbVie

Bellaire, TX · Fort Worth, TX · Garland, TX · +57 more sites

RecruitingPhase 3NCT07577843

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Janssen Research & Development, LLC

Tyler, TX · +21 more sites

RecruitingPhase 3NCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Sponsor: Merck Sharp & Dohme LLC

Austin, TX · Fort Worth, TX · San Antonio, TX · +46 more sites

RecruitingPhase 3NCT06307652

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Sponsor: AstraZeneca

Allen, TX · Amarillo, TX · +163 more sites

RecruitingPhase 3NCT06307665

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Sponsor: AstraZeneca

Austin, TX · Baytown, TX · Beaumont, TX · +117 more sites

RecruitingPhase 3NCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Sponsor: Merck Sharp & Dohme LLC

Dallas, TX · +43 more sites

RecruitingPhase 3NCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Sponsor: Merck Sharp & Dohme LLC

Dallas, TX · Denton, TX · +84 more sites

RecruitingPhase 3NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Sponsor: Bristol-Myers Squibb

Austin, TX · Tyler, TX · +18 more sites

RecruitingPhase 3NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Sponsor: Merck Sharp & Dohme LLC

Fort Worth, TX · Houston, TX · San Antonio, TX · +50 more sites

RecruitingPhase 3NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Sponsor: Pfizer

Abilene, TX · Allen, TX · Amarillo, TX · +238 more sites

RecruitingPhase 3NCT07216703

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Sponsor: Merck Sharp & Dohme LLC

Fort Worth, TX · Houston, TX · The Woodlands, TX · +27 more sites

RecruitingPhase 3NCT07577856

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

Sponsor: Janssen Research & Development, LLC

San Antonio, TX · Tyler, TX · +22 more sites

RecruitingPhase 2NCT06226883

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Cedar Park, TX · Denton, TX · Houston, TX · +22 more sites

RecruitingPhase 2NCT07186101

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Sponsor: Eli Lilly and Company

Cedar Park, TX · Dallas, TX · Fort Worth, TX · +37 more sites

RecruitingPhase 3NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Pfizer

Abilene, TX · Allen, TX · Amarillo, TX · +223 more sites

RecruitingPhase 3NCT07222800

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Sponsor: Pfizer

Abilene, TX · Amarillo, TX · Beaumont, TX · +251 more sites

RecruitingPhase 2NCT07415044

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Sponsor: Eli Lilly and Company

Fort Worth, TX · Garland, TX · Houston, TX · +49 more sites

RecruitingPhase 3NCT07794579

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Sponsor: Eli Lilly and Company

Austin, TX · Brownsville, TX · Dallas, TX · +77 more sites

RecruitingPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Sponsor: Genmab

Abilene, TX · Austin, TX · Dallas, TX · +34 more sites

RecruitingPhase 3NCT06937086

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Sponsor: Eli Lilly and Company

San Antonio, TX · Tyler, TX · +34 more sites

RecruitingPhase 3NCT06937099

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Sponsor: Eli Lilly and Company

San Antonio, TX · Tyler, TX · +32 more sites

RecruitingPhase 3NCT07228832

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Sponsor: Summit Therapeutics

Dallas, TX · Fort Worth, TX · +109 more sites

RecruitingNot applicableNCT07069738

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

Sponsor: Boston Scientific Corporation

Plano, TX · Tyler, TX · +40 more sites

RecruitingPhase 3NCT06651281

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Sponsor: Merck Sharp & Dohme LLC

Garland, TX · Lubbock, TX · +9 more sites

RecruitingPhase 1NCT05176483

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Sponsor: Exelixis

Austin, TX · Dallas, TX · +43 more sites

RecruitingPhase 1 / Phase 2NCT06996782

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Sponsor: AstraZeneca

Tyler, TX · +9 more sites

RecruitingPhase 3NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Sponsor: Bristol-Myers Squibb

Amarillo, TX · Austin, TX · Denton, TX · +35 more sites

RecruitingPhase 1 / Phase 2NCT06619990

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Sponsor: Xencor, Inc.

Cedar Park, TX · Denton, TX · Garland, TX · +27 more sites

RecruitingPhase 2NCT07845487

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

Sponsor: Palisade Bio

Garland, TX · Georgetown, TX · Houston, TX · +27 more sites

RecruitingPhase 3NCT06819891

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Hoffmann-La Roche

Dallas, TX · Fort Worth, TX · Garland, TX · +58 more sites

RecruitingPhase 3NCT07277231

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Sponsor: BeOne Medicines

Tyler, TX · +21 more sites

RecruitingPhase 3NCT07761117

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Sponsor: AstraZeneca

Dallas, TX · DeSoto, TX · El Paso, TX · +117 more sites

RecruitingPhase 2NCT06233461

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Takeda

Bellaire, TX · Dallas, TX · Fort Worth, TX · +27 more sites

RecruitingPhase 2NCT06548542

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Sponsor: AbbVie

Cedar Park, TX · El Paso, TX · Garland, TX · +61 more sites

RecruitingPhase 3NCT06852222

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Sponsor: Janssen Research & Development, LLC

Dallas, TX · Houston, TX · +56 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.